[Quality of treatment after myocardial infarction: impact of hospital guidelines]

Vera von Gunten; Christophe Sierro; Séverine Rosiak; Marie-Laure Weibel; Pierre-August Petignat; Grégoire Girod; Johnny Beney

[Quality of treatment after myocardial infarction: impact of hospital guidelines]

Rev Med Suisse. 2013 Nov 13;9(406):2107-11.

[Article in French]

Authors

Vera von Gunten¹, Christophe Sierro², Séverine Rosiak³, Marie-Laure Weibel³, Pierre-August Petignat⁴, Grégoire Girod², Johnny Beney⁵

Affiliations

¹ Service de Pharmacie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion. vera.vongunten@hospitalvs.ch
² Service de Cardiologie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion.
³ Pharmacie des Hôpitaux de l'Est lémanique, Hôpital Riviera, site du Samaritain, Vevey.
⁴ Service de Médecine Interne du Centre hospitalier du Valais romand, Hôpital du Valais, Sion.
⁵ Service de Pharmacie du Centre hospitalier du Valais romand, Hôpital du Valais, Sion.

PMID: 24383285

Abstract

After myocardial infarction (MI), international societies of cardiology recommend an optimal treatment associating four classes of drugs, known as BASI combination (beta-blocker, antiplatelets, statin and inhibitor of the angiotensin converting enzyme). This study shows that the implementation of locally adapted guidelines in a regional hospital (CHCVs, Sion) significantly improve the treatment quality after MI, with a 10% increase of the BASI combination at discharge. Detailed results are discussed. Finally, we provide a table summarizing the optimal treatment strategy with drug examples including doses, which will be helpful to both general practitioners and specialists.

Publication types

English Abstract

MeSH terms

Adrenergic beta-Antagonists / administration & dosage
Adrenergic beta-Antagonists / therapeutic use
Aged
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Drug Therapy, Combination
Female
Hospitals / standards
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Male
Myocardial Infarction / drug therapy*
Platelet Aggregation Inhibitors / administration & dosage
Platelet Aggregation Inhibitors / therapeutic use
Practice Guidelines as Topic*
Quality of Health Care*
Retrospective Studies
Societies, Medical

Substances

Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Platelet Aggregation Inhibitors